







In the format provided by the authors and unedited.

# The E3 ubiquitin ligase SPOP controls resolution of systemic inflammation by triggering MYD88 degradation

**Maria Guillamot** <sup>1,2,10\*</sup>, **Dahmane Ouazia**<sup>3,10</sup>, **Igor Dolgalev**<sup>1,2,4</sup>, **Stephen T. Yeung**<sup>5</sup>, **Nikos Kourtis**<sup>1,2</sup>, **Yuling Dai**<sup>1,2</sup>, **Kate Corrigan**<sup>1,2</sup>, **Luna Zea-Redondo**<sup>1,2</sup>, **Anita Saraf**<sup>6</sup>, **Laurence Florens**<sup>6</sup>, **Michael P. Washburn**<sup>6,7</sup>, **Anastasia N. Tikhonova**<sup>1,2</sup>, **Marina Malumbres**<sup>1,2</sup>, **Yixiao Gong**<sup>1,2</sup>, **Aristotelis Tsirigos** <sup>1,2,4</sup>, **Christopher Park**<sup>1,2</sup>, **Christopher Barbieri**<sup>8,9</sup>, **Kamal M. Khanna** <sup>5</sup>, **Luca Busino** <sup>3,10,11\*</sup> and **Iannis Aifantis** <sup>1,2,10,11\*</sup>


<sup>1</sup>Department of Pathology, NYU School of Medicine, New York, NY, USA. <sup>2</sup>Laura and Isaac Perlmutter Cancer Center, NYU School of Medicine, New York, NY, USA. <sup>3</sup>Department of Cancer Biology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. <sup>4</sup>Applied Bioinformatics Laboratories, Office of Science & Research, NYU School of Medicine, New York, NY, USA. <sup>5</sup>Department of Microbiology, NYU School of Medicine, New York, NY, USA. <sup>6</sup>The Stowers Institute of Medical Research, Kansas City, MO, USA. <sup>7</sup>Department of Pathology and Laboratory Medicine, The University of Kansas Medical Center, Kansas City, KS, USA. <sup>8</sup>Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA. <sup>9</sup>Department of Urology, Weill Cornell Medicine, New York, NY, USA. <sup>10</sup>These authors contributed equally: Maria Guillamot, Dahmane Ouazia. <sup>11</sup>These authors jointly supervised this work: Luca Busino and Iannis Aifantis. \*e-mail: [maria.guillamot-ruano@nyumc.org](mailto:maria.guillamot-ruano@nyumc.org); [businol@upenn.edu](mailto:businol@upenn.edu); [iannis.aifantis@nyumc.org](mailto:iannis.aifantis@nyumc.org)



## Supplementary Figure 1

*Spop* is highly expressed in LT-HSC.


**a**, Top 15 highest expressed ubiquitin ligase genes in LT-HSC. Heatmap represents the normalized counts relative to 10M reads per gene in the indicated populations. The data was collected from Lara-Astiaso., 2016<sup>29</sup> **b**, *Spop* expression profile on different hematopoietic cells from the same dataset. **c**, Immunoblot showing *Spop* protein levels in the indicated sorted cells. Data are representative from two independent experiments **d**, Schematic diagram of *Spop* conditional allele. **e**, Immunoblot analysis of *Spop* protein levels of total bone marrow cells from wild-type (*Spop*<sup>+/+</sup>MxCre) and KO (*Spop* <sup>$\Delta/\Delta$</sup> MxCre) mice following a single Poly(I:C) injection. Data are representative of three independent experiments. **f**, Percentage of mouse weight-change on d15 after Poly (I:C) injection (*Spop*<sup>+/+</sup>MxCre: n=9; *Spop* <sup>$\Delta/\Delta$</sup> MxCre: n=10). Data represent minimum, first quartile, mean, third quartile and maximum. Statistical analysis: unpaired t-test, two-tailed). **g**, Kaplan-Meier analysis of survival of *Spop*<sup>+/+</sup>MxCre and *Spop* <sup>$\Delta/\Delta$</sup> MxCre hematopoietic chimeras after donor hematopoietic reconstitution and one injection of Poly(I:C) (n=5 wild-type, n=6 *Spop* KO. Statistical analysis: Mantel-Cox test). **h**, Hematoxylin & Eosin stained sections of spleen, lung and liver of wild-type (*Spop*<sup>+/+</sup>MxCre) and KO (*Spop* <sup>$\Delta/\Delta$</sup> MxCre) hematopoietic chimeric mice on d21 post Poly (I:C) injection. Scale bars indicate 100  $\mu$ m (Spleen and liver), 1000  $\mu$ m (lung) and 10  $\mu$ m magnifications. Data are representative from 3 independent experiments(pl:C: Poly (I:C). LT-HSC: Lin<sup>-</sup>c-Kit<sup>+</sup>Sca-1<sup>+</sup>Fli2<sup>+</sup>CD34<sup>+</sup>. ST-HSC: Lin<sup>-</sup>c-Kit<sup>+</sup>Sca-1<sup>+</sup>Fli2<sup>+</sup>CD34<sup>+</sup>. MPP: Lin<sup>-</sup>c-Kit<sup>+</sup>Sca-1<sup>+</sup>Fli2<sup>+</sup>CD34<sup>+</sup>. CMP: Lin<sup>-</sup>c-Kit<sup>+</sup>Sca-1<sup>+</sup>FcgRII<sup>low</sup>CD34<sup>+</sup>. GMP: Lin<sup>-</sup>c-Kit<sup>+</sup>Sca-1<sup>+</sup>FcgRII<sup>high</sup>CD34<sup>+</sup>. MEP: Lin<sup>-</sup>c-Kit<sup>+</sup>Sca-1<sup>+</sup>FcgRII<sup>high</sup>CD34<sup>+</sup>. CLPs: Lin<sup>-</sup>Fli2<sup>+</sup>II7R<sup>+</sup>).



## Supplementary Figure 2

Gating strategy.


Representative image of the Flow Cytometry gating strategy to identify B-, T- and myeloid cells in peripheral blood and bone marrow of the mice and HSC and progenitors in the bone marrow of the mice.



### Supplementary Figure 3

*Spop<sup>Δ</sup>MxCre* neutrophils display upregulation of inflammatory response gene programs.


**a**, GSEA enrichment plots of differentially expressed genes in *Spop* KO *Spop<sup>Δ/Δ</sup>MxCre* neutrophils (n=3 mice) compare to control *Spop<sup>+/+</sup>MxCre* (n=2 mice). Statistical significance determined by GSEA Nominal p-value **b**, Heatmap showing the relative expression of selected Toll-like and NF-κB signaling genes identified to be upregulated in *Spop* KO compare to controls. **c**, Heatmap showing the relative expression of selected interferon response genes identified to be upregulated in *Spop* KO compare to controls. **d**, Ingenuity upstream analysis of differentially expressed genes in *Spop<sup>Δ</sup>MxCre* neutrophils compare to control. **e**, ENRICH transcription factor analysis of the identified differential upregulated genes in *Spop* KO neutrophils compare to control. (NES: normalized enrichment score).



**Supplementary Figure 4**

Granulocytic specific *Spop* deletion does not promote neutrophilia.

**a**, Immunoblot analysis of *Spop* protein levels of bone marrow cKit<sup>+</sup> cells of wild type, *Spop* $\Delta/\Delta$ MxCre and *Spop* $\Delta/\Delta$ CreERT2 mice after Poly(I:C) or Tamoxifen treatment. **b**, Percentage of myeloid (CD11b<sup>+</sup>Ly6G<sup>+</sup>) cells in the peripheral blood of *Spop* KO and control hematopoietic chimeras on the indicated times after Tamoxifen treatment. Data represent mean $\pm$ s.d. and dots represent different mice. Statistical analysis: unpaired t-test (two-tailed). **c**, Representative flow cytometry analysis plots of the proportion of myeloid (CD11b<sup>+</sup>Ly6G<sup>+</sup>) cells in the peripheral blood of *Spop* KO and control hematopoietic chimeras on d15 after a sub-lethal LPS injection. **d**, Representative flow cytometry analysis plots of the proportion of myeloid (CD11b<sup>+</sup>Ly6G<sup>+</sup>) cells in the peripheral blood of *Spop* KO (and control hematopoietic chimeric mice on the indicated days after intranasal influenza inoculation. **e**, *Spop* mRNA relative expression levels in the indicated sorted bone marrow cells. Data represent mean $\pm$ s.d. (n=3 mice per genotype). The results were first standardized for *Gapdh* expression levels and then each *Spop* $\Delta/\Delta$  sample was expressed as a fraction of the expression detected in the correlated control population from the control littermate. **f**, Percentage of myeloid (CD11b<sup>+</sup>Ly6G<sup>+</sup>) cells in the peripheral blood of the indicated mice on d10 following plpC-challenge (n=5 per genotype). Data represent mean $\pm$ s.d. and dots represent different mice. Statistical analysis: unpaired t-test (two-tailed). **a-f**, Data representative of 3 independent experiments.




### Supplementary Figure 5

Conditional deletion of *Spop* leads to HSPC expansion and myeloid skewing.

**a**, Representative flow cytometry analysis plot of Lineage negative bone marrow cells at the indicated days after Poly (I:C) injection. **b**,

Representative flow cytometry analysis plots of the proportion of HSPC populations, including LSK (Lineage<sup>-</sup>Sca-1<sup>+</sup>Kit<sup>+</sup>), LK (Lineage<sup>-</sup>Sca-1<sup>+</sup>Kit<sup>+</sup>), HSC (LSK CD135<sup>-</sup>, CD48<sup>-</sup> CD150<sup>+</sup>), MPP2 (LSK CD135<sup>-</sup> CD48<sup>+</sup> CD150<sup>+</sup>), MPP3 (LSK CD135<sup>-</sup> CD48<sup>+</sup> CD150<sup>-</sup>), CMP (LK FcyR<sup>low</sup> CD34<sup>+</sup>), GMP (LK FcyR<sup>high</sup> CD34<sup>+</sup>), MEP (LK FcyR<sup>low</sup> CD34<sup>+</sup>). **c**, Percentage of LSK and LK populations in the total bone marrow, percentage of HSC, MPP2, MPP3 and MPP4 in LSKs and percentage of CMP, GMP and MEP in LKs (n=4 mice per genotype). Data represent mean±s.d and dots represent different mice. Statistical analysis: unpaired t-Student, two-tailed). **a-d** Data are representative from 3 independent experiment. **d**, Heatmap showing the relative expression of the selected GSEA-analyzed leading edge genes in *Spop*<sup>Δ/Δ</sup>MxCre and control sorted LSKs (n=2 mice per genotype) together with control HSC, MPP, CMP, GMP and GN (Granulocyte) wild-type populations from *Lara-Astiaso et al., 2016*. **e**, GSEA enrichment plots for HSC, MPP3, MPP4 and granulocytic and macrophage precursor signatures<sup>45</sup> in *Spop*<sup>Δ/Δ</sup>MxCre and control sorted LSKs (n=2 per genotype). Statistical analysis: Normalized Enrichment Score (NES) and GSEA Nominal p-value. **f**, Cytokine levels in the serum of the indicated hematopoietic chimeras following one pl:C injection (n=4 per genotype and condition). **g**, Cytokine levels in the bone marrow fluids of the indicated hematopoietic chimeras following one pl:C injection. **f,g** Data represent mean±s.d and dots represent different mice. Data are representative of two independent experiments.(h=hours, d=days)




Supplementary Figure 6



Defined gene signature per HSPC clusters.

**a**, Heatmap showing the expression levels of the 50 most significant markers per cluster, displaying 100 randomly-selected cells of wild-type (*Spop*<sup>+/+</sup>MxCre) and *Spop* KO (*Spop*<sup>Δ/Δ</sup>MxCre) LSK. \* indicate the upregulation of the C5 specific signature in the cells of other clusters. **b**, Normalized expression levels of selected population-specific-markers across clusters (C1=4714, C2=2461, C3=1649, C4=1689, C5=1328, C6=1030, C7=196 cells) Data represent mean±s.d. **c**, Spectral tSNE plot of *Spop* wild-type (8184) and KO (4920) LSK cells showing the Enrichment Score for Emergency Megakaryocyte gene signature. **d**, Percentage of Megakaryocyte progenitors (Lineage<sup>-</sup>, Sca-1<sup>-</sup>, Kit<sup>-</sup>, CD150<sup>+</sup>, CD41<sup>+</sup>) from total progenitor (Lineage<sup>-</sup>cKit<sup>+</sup>Sca-1<sup>+</sup>) cells from the indicated mice (n=4 per genotype and time-point). **e**, Spectral tSNE plot of *Spop* wild-type (8184) and KO (4920) LSK cells showing the Enrichment Score for Emergency Granulopoietic gene signature. **f**, Cell differentiation trajectory using PHATE visualization of wild-type and *Spop* KO cells, color code for HSC (n=1099), MPP2 (Megakaryocyte/Erythroid biased, n=5111), MPP3 (myeloid biased, n=2414) or MPP4 (lymphoid biased, n=3737) gene signatures. **g**, Spectral tSNE plot of cell cycling color-coded cells. **h**, Frequency of cells expressing cell cycle genes in *Spop*<sup>Δ/Δ</sup>MxCre and control LSKs. **i**, Percentage of *Spop*<sup>Δ/Δ</sup>MxCre and control cell cycling (EdU<sup>+</sup>) LSKs on d10 post a Poly (I:C) injection. Data represent mean±s.d. n=3. Statistical analysis: unpaired t-student, two-tailed. **d,i**, Data are representative from 2 independent experiments




**Supplementary Figure 7**

SPOP interacts with MYD88 in a phosphorylation independent manner to inhibit IRAK4 signalling.

**a**, Left, overall view of the SPOP-BTB dimer (pdb access code = 3HTM (Zhuang *et al.*, 2009)) with protomers in green and cyan. Right, overall view of dimer interface rotated 90° in x. The L193 residue on each protomer is shown in red. The structural images were obtained using UCSF chimera software. **b**, Immunoblot analysis of whole cell lysates from K562 cells stably expressing HA-tagged SPOP(WT) and SPOP(L193P). Cells were treated with cycloheximide (CHX) for the indicated times. EV, empty vector. **c**, Top, immunoblot analysis of immunoprecipitated WT and truncated forms of FLAG-tagged MYD88 transiently expressed in HEK 293T cells. EV, empty vector. Bottom, diagram showing MYD88 truncations as well as the differential binding to SPOP. **d**, Immunoblot analysis of immunoprecipitated FLAG-tagged MYD88 and of FLAG-tagged CDC25A, both transiently expressed in HEK293T cells. Equal volumes of the immunopurified protein were both treated with the λ-phosphatase reaction buffer with or without the enzyme. EV, empty vector. **e**, Immunoblot analysis of immunoprecipitated FLAG-tagged MYD88(WT) and phosphomimetic mutants (S136D, S137D, S136D/S137D) transiently expressed in HEK 293T cells. EV, empty vector. **f**, *In vivo* ubiquitylation of immunoprecipitated FLAG-tagged MYD88 upon co-expression with HA-tagged SPOP and increasing amounts of HA-tagged IRAK4 in HEK293T cells. A low (l.e.) and high exposure


(h.e.) are shown. Protein purification was performed in denaturing conditions. **g**, Immunoblot analysis of immunoprecipitated FLAG-tagged MYD88 co-expressed with HA-tagged SPOP and either HA-tagged IRAK4(WT) or kinase dead (KD) mutant in HEK293T cells. Protein purification was performed in denaturing conditions. **h**, Immunoblot analysis of whole cell lysates of HPC-7 cells *Spop*-WT and *Spop*-KO. Cells were treated with 10 µg/ml lipopolysaccharides (LPS) for the indicated times. A low (l.e.) and high exposure (h.e.) are shown. **a-h** Data are representative from 3 independent experiments



### Supplementary Figure 8

Spop loss of function reshapes the open chromatin landscape of the HSPCs.

**a**, Venn-diagram showing the ATAC-seq signals common and unique for wild-type ( $Spop^{+/+}MxCre$   $n=2$  mice) and  $Spop^{\Delta/\Delta}MxCre$  ( $n=2$  mice) LSKs (Lineage<sup>c</sup>Kit<sup>+</sup>Sca-1<sup>+</sup> bone marrow cells), sorted on d10 following a Poly (I:C) injection (FDR<0.05). **b**, GREAT Gene Ontology Biological Function analysis of the 25570  $Spop^{\Delta}MxCre$  differential open chromatin elements. Statistical analysis: GREAT enrichment binomial test from GREAT **c**, Genome Browser plots showing the normalized ATAC-seq profiles at the promoter and distal elements of the indicated genes for *wild-type* (blue) and  $Spop^{\Delta}MxCre$  (green) samples. Data are representative from two mice per genotype. **d**, Ranking of the most enriched transcription factor (TF) motif within  $Spop^{\Delta}MxCre$  vs wild-type differential open chromatin elements (cumulative binomial distribution  $P < 10^{-10}$ ). Green=TF motif enriched in the  $Spop^{\Delta/\Delta}MxCre$  differential open chromatin elements. Blue=TF motif enriched in the  $Spop^{+/+}MxCre$  differential open chromatin elements. Black= TF motif enriched in the  $Spop^{\Delta/\Delta}MxCre$  vs  $Spop^{+/+}MxCre$  differential open chromatin elements. Statistical analysis: HOMER enrichment binomial test **e**, ATAC-seq Footprint visualization for the indicated TF. Aggregated plot of the Tn5 (transposase) insertions counts per nucleotide.




### Supplementary Figure 9

*Myd88* deficiency restores the steady-state transcriptional program in *Spop* KO LSKs.


a, Representative flow cytometry analysis plots of the proportion of HSPC in the lineage<sup>-</sup> bone marrow from hematopoietic chimeric mice following Poly(I:C) injection including: control (*Spop*<sup>+/+</sup>*MxCre* *MyD88*<sup>+/+</sup>), *Spop* KO (*Spop*<sup>Δ/Δ</sup>*MxCre* *MyD88*<sup>+/+</sup>), *Myd88* KO (*Spop*<sup>+/+</sup>*MxCre* *MyD88*<sup>-/-</sup>) and dKO (*Spop*<sup>Δ/Δ</sup>*MxCre* *MyD88*<sup>-/-</sup>). Data are representative from 2 independent experiments. b, *Spop* mRNA expression levels of LSKs on d10 post Poly (I:C) injection (n=2). c, Immunoblot analysis of HSPC cKit<sup>+</sup> bone marrow cells of wild-type (*Spop*<sup>+/+</sup>*MxCre* *MyD88*<sup>+/+</sup>), *Spop* KO (*Spop*<sup>Δ/Δ</sup>*MxCre* *MyD88*<sup>+/+</sup>) and dKO (*Spop*<sup>+/+</sup>*MxCre* *MyD88*<sup>-/-</sup>) mice. Data are representative from 3 independent experiments. d, Heatmap showing the expression levels of the 50 most significant markers per cluster, displaying 100 randomly-selected cells. e, Percentage of Cycling cells per genotype. f, Percentage of myeloid Cd11b+Ly6G+ cells in peripheral blood. g, Flow cytometry analysis of CD11b-PeCy7 vs Ly6G-FITC.

of *Spop<sup>Δ</sup>*MxCre mice on day 20 following plpC challenge and antibody treatment. Bar plots represent mean±s.d, n=4 mice per condition. g, Representative Flow Cytometry Analysis Plots of the proportion of Myeloid (Cd11b+, Ly6G+) cells in the peripheral blood of the plpC-stimulated mice.



Uncropped gels

Uncropped western blot gels from the indicated figures



Uncropped gels 2

Uncropped western blot gels